Targeting DNA damage repair precision medicine strategies in cancer

Juliette Brownlie(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Sanat Kulkarni(Sandwell & West Birmingham Hospitals NHS Trust), Jennie Jeyapalan(University of Nottingham), Nigel P. Mongan(University of Nottingham), Mashael Algethami(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Current Opinion in Pharmacology
May 4, 2023
10.1016/j.coph.2023.102381
Cited by 19

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282